<DOC>
	<DOCNO>NCT01163058</DOCNO>
	<brief_summary>Aim present retrospective study evaluate molecular factor primary resistance tyrosine kinase inhibitor metastatic non small cell lung cancer ( NSCLC ) patient . The investigator assess first , incidence epidermal growth factor receptor ( EGFR ) Kirsten ras sarcoma viral oncogene homolog ( KRAS ) mutation , SOS hepatocyte growth factor ( HGF ) expression , anaplastic lymphoma kinase ( ALK ) translocation expression , secondly , investigator correlate molecular marker clinical feature outcome term response rate , progression free survival overall survival .</brief_summary>
	<brief_title>Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description>Non small cell lung cancer patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Histologically confirm diagnosis NSCLC ( non small cell lung cancer ) available tumor tissue mutational analysis Metastatic disease treat gefitinib erlotinib Presence least one measurable lesion accord RECIST criterion No tumor tissue available No clinical data available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>